Drugs facing NCE-1 in 2026

1. Amvuttra patent expiration

AMVUTTRA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10131907 ALNYLAM PHARMS INC Glycoconjugates of RNA interference agents
Aug, 2028

(3 years from now)

US10806791 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(3 years from now)

US9370581 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(3 years from now)

US8828956 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2028

(3 years from now)

US8106022 ALNYLAM PHARMS INC Carbohydrate conjugates as delivery agents for oligonucleotides
Dec, 2029

(4 years from now)

US9399775 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(7 years from now)

US10570391 ALNYLAM PHARMS INC RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
Nov, 2032

(7 years from now)

US10612024 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(10 years from now)

US11401517 ALNYLAM PHARMS INC Modified double-stranded RNA agents
Aug, 2035

(10 years from now)

US10208307 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(11 years from now)

US10683501 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(11 years from now)

US11286486 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(11 years from now)

US12049628 ALNYLAM PHARMS INC Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
Jul, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 13, 2027
Orphan Drug Exclusivity(ODE-212) Jun 13, 2029

Drugs and Companies using VUTRISIRAN SODIUM ingredient

NCE-1 date: 13 June, 2026

Market Authorisation Date: 13 June, 2022

Treatment: Amvuttra is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults

Dosage: SOLUTION

More Information on Dosage

AMVUTTRA family patents

Family Patents

2. Baxdela patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9539250 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(9 months from now)

US8273892 MELINTA Salt and crystalline forms thereof of a drug
Aug, 2026

(1 year, 7 months from now)

US8871938 MELINTA Process for making quinolone compounds
Sep, 2029

(4 years from now)

USRE46617 MELINTA Process for making quinolone compounds
Dec, 2029

(5 years from now)

US8497378 MELINTA Process for making quinolone compounds
Dec, 2029

(5 years from now)

US7728143 MELINTA Salt and crystalline forms thereof of a drug
Jun, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8969569 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(9 months from now)

US8648093 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2025

(9 months from now)

US8252813 MELINTA Salt and crystalline forms thereof of a drug
Oct, 2026

(1 year, 9 months from now)

US9750822 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9200088 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US8410077 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US7635773 MELINTA Sulfoalkyl ether cyclodextrin compositions
Mar, 2029

(4 years from now)

US9493582 MELINTA Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(8 years from now)

US12036219 MELINTA Methods of treating infections in overweight and obese patients using antibiotics
Jun, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 19, 2022
New Indication(I-815) Oct 24, 2022
Generating Antibiotic Incentives Now(GAIN) Jun 19, 2027

Drugs and Companies using DELAFLOXACIN MEGLUMINE ingredient

NCE-1 date: 19 June, 2026

Market Authorisation Date: 19 June, 2017

Treatment: Treatment of acute bacterial skin and skin structure infections caused by designated susceptible bacteria in adults; Treating an acute bacterial skin and skin structure infection (absssi) in an overwe...

Dosage: POWDER; TABLET

More Information on Dosage

BAXDELA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Bludigo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11845867 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Nov, 2036

(11 years from now)

US10927258 PROVEPHARM SAS Process for the preparation of Indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)

US11499050 PROVEPHARM SAS Process for the preparation of indigotindisulfonate sodium (indigo carmine)
Dec, 2037

(13 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jul 08, 2027

Drugs and Companies using INDIGOTINDISULFONATE SODIUM ingredient

NCE-1 date: 08 July, 2026

Market Authorisation Date: 08 July, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

BLUDIGO family patents

Family Patents

4. Bosulif patent expiration

BOSULIF's oppositions filed in EPO
BOSULIF IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6002008 PF PRISM CV Substituted 3-cyano quinolines
Mar, 2018

(6 years ago)

USRE42376 PF PRISM CV Substituted 3-cyanoquinolines
Apr, 2024

(8 months ago)

US7767678 PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
Nov, 2026

(1 year, 11 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6002008 PF PRISM CV Substituted 3-cyano quinolines
Mar, 2018

(6 years ago)

USRE42376

(Pediatric)

PF PRISM CV Substituted 3-cyanoquinolines
Oct, 2024

(2 months ago)

US7919625 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(11 months from now)

US7417148 PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Dec, 2025

(11 months from now)

US7919625

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(1 year, 5 months from now)

US7417148

(Pediatric)

PF PRISM CV 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML)
Jun, 2026

(1 year, 5 months from now)

US7767678

(Pediatric)

PF PRISM CV Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same
May, 2027

(2 years from now)

US11103497 PF PRISM CV Treatment of imatinib resistant leukemia
Feb, 2034

(9 years from now)

US11103497

(Pediatric)

PF PRISM CV Treatment of imatinib resistant leukemia
Aug, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 04, 2017
Orphan Drug Exclusivity(ODE) Sep 04, 2019
Orphan Drug Exclusivity(ODE-30) Sep 04, 2019
New Indication(I-759) Dec 19, 2020
Orphan Drug Exclusivity(ODE-163) Dec 19, 2024
New Indication(I-923) Sep 26, 2026
New Product(NP) Sep 26, 2026
Pediatric Exclusivity(PED) Mar 26, 2027
Orphan Drug Exclusivity(ODE-444) Sep 26, 2030

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

NCE-1 date: 26 March, 2026

Market Authorisation Date: 04 September, 2012

Treatment: A method of treating a neoplasm; A method of treating patients 1 year of age and older with chronic phase ph+ cml, newly-diagnosed or resistant or intolerant to prior therapy; A method for treating a ...

Dosage: TABLET

How can I launch a generic of BOSULIF before it's drug patent expiration?
More Information on Dosage

BOSULIF family patents

Family Patents

5. Camzyos patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE50050 BRISTOL Pyrimidinedione compounds
Jun, 2034

(9 years from now)

US9181200 BRISTOL Pyrimidinedione compounds
Jun, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9585883 BRISTOL Pyrimidinedione compounds
Jun, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-297) Jun 15, 2026
New Chemical Entity Exclusivity(NCE) Apr 28, 2027
Orphan Drug Exclusivity(ODE-398) Apr 28, 2029

Drugs and Companies using MAVACAMTEN ingredient

NCE-1 date: 28 April, 2026

Market Authorisation Date: 28 April, 2022

Treatment: Treatment of adults with symptomatic new york heart association (nyha) class ii-iii obstructive hypertrophic cardiomyopathy (hcm) to improve functional capacity and symptoms

Dosage: CAPSULE

More Information on Dosage

CAMZYOS family patents

Family Patents

6. Cibinqo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9545405 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

US9035074 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929 PFIZER Pyrrolo[2,3-D]pyrimidine derivatives
Feb, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Feb 09, 2026
New Chemical Entity Exclusivity(NCE) Jan 14, 2027

Drugs and Companies using ABROCITINIB ingredient

NCE-1 date: 14 January, 2026

Market Authorisation Date: 14 January, 2022

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET

More Information on Dosage

CIBINQO family patents

Family Patents

7. Elucirem patent expiration

ELUCIREM's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8114863 GUERBET Compounds comprising short aminoalcohol chains and metal complexes for medical imaging
Sep, 2028

(3 years from now)

US10973934 GUERBET Gadolinium bearing PCTA-based contrast agents
Aug, 2039

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11590246 GUERBET Complex of gadolinium and a chelating ligand derived from a diastereoisomerically enriched PCTA and preparation and purification process
Jan, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 21, 2027

Drugs and Companies using GADOPICLENOL ingredient

NCE-1 date: 21 September, 2026

Market Authorisation Date: 21 September, 2022

Treatment: NA

Dosage: SOLUTION

More Information on Dosage

ELUCIREM family patents

Family Patents

8. Farxiga patent expiration

FARXIGA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(4 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(4 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(4 years ago)

US9238076 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2024

(8 months ago)

US8461105 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device
Apr, 2025

(3 months from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device
Jun, 2025

(6 months from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Oct, 2025

(9 months from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device
Dec, 2025

(1 year, 10 days from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 3 months from now)

US8906851 ASTRAZENECA AB Method for treating diabetes
Aug, 2026

(1 year, 7 months from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Aug, 2026

(1 year, 7 months from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight
Feb, 2027

(2 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes
Feb, 2027

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Mar, 2028

(3 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Aug, 2028

(3 years from now)

US8221786

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(3 years from now)

US8716251

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(3 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Sep, 2028

(3 years from now)

US7851502

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Feb, 2029

(4 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder
Jan, 2030

(5 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US7919598

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2030

(5 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder
Jul, 2030

(5 years from now)

US8685934

(Pediatric)

ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
Nov, 2030

(5 years from now)

US11826376 ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jul, 2039

(14 years from now)

US11826376

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same
Jan, 2040

(15 years from now)

US11903955 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Mar, 2040

(15 years from now)

US10973836

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Sep, 2040

(15 years from now)

US11903955

(Pediatric)

ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction
Sep, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
M(M-157) Mar 11, 2018
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-212) Oct 20, 2020
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Indication(I-834) May 05, 2023
New Indication(I-857) Apr 30, 2024
M(M-298) May 08, 2026
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 08 January, 2014

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release compositio...

Dosage: TABLET

How can I launch a generic of FARXIGA before it's drug patent expiration?
More Information on Dosage

FARXIGA family patents

Family Patents

9. Krazati patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10689377 BRISTOL KRas G12C inhibitors
May, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 12, 2027
Orphan Drug Exclusivity(ODE-352) Dec 12, 2029

Drugs and Companies using ADAGRASIB ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 12 December, 2022

Treatment: Treatment, in combination with cetuximab, of adult patients with kras g12c-muted locally advanced or metastatic colorectal cancer, per fda approved test, where prior treatment with fluoropyrimidine-, ...

Dosage: TABLET

More Information on Dosage

KRAZATI family patents

Family Patents

10. Lenvima patent expiration

LENVIMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7253286 EISAI INC Nitrogen-containing aromatic derivatives
Oct, 2025

(10 months from now)

US7612208 EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Sep, 2026

(1 year, 8 months from now)

US10407393 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(10 years from now)

US10259791 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(10 years from now)

US11186547 EISAI INC High-purity quinoline derivative and method for manufacturing same
Aug, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7253286

(Pediatric)

EISAI INC Nitrogen-containing aromatic derivatives
Apr, 2026

(1 year, 4 months from now)

US7612208

(Pediatric)

EISAI INC Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt and a process for preparing the same
Mar, 2027

(2 years from now)

US9006256 EISAI INC Antitumor agent for thyroid cancer
Jul, 2027

(2 years from now)

US9006256

(Pediatric)

EISAI INC Antitumor agent for thyroid cancer
Jan, 2028

(3 years from now)

US11090386 EISAI INC Method for suppressing bitterness of quinoline derivative
Feb, 2036

(11 years from now)

US10407393

(Pediatric)

EISAI INC High-purity quinoline derivative and method for manufacturing same
Feb, 2036

(11 years from now)

US10259791

(Pediatric)

EISAI INC High-purity quinoline derivative and method for manufacturing same
Feb, 2036

(11 years from now)

US11186547

(Pediatric)

EISAI INC High-purity quinoline derivative and method for manufacturing same
Feb, 2036

(11 years from now)

US12083112 EISAI INC Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
Mar, 2036

(11 years from now)

US11090386

(Pediatric)

EISAI INC Method for suppressing bitterness of quinoline derivative
Aug, 2036

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-734) May 13, 2019
New Chemical Entity Exclusivity(NCE) Feb 13, 2020
New Indication(I-787) Aug 15, 2021
Orphan Drug Exclusivity(ODE) Feb 13, 2022
Orphan Drug Exclusivity(ODE-87) Feb 13, 2022
New Indication(I-807) Sep 17, 2022
M(M-269) Jul 21, 2024
New Indication(I-868) Aug 10, 2024
M(M-272) Dec 19, 2024
Orphan Drug Exclusivity(ODE-196) Aug 15, 2025
M(M-14) Apr 03, 2027
Pediatric Exclusivity(PED) Oct 03, 2027

Drugs and Companies using LENVATINIB MESYLATE ingredient

NCE-1 date: 03 October, 2026

Market Authorisation Date: 13 February, 2015

Treatment: Method for treating thyroid carcinoma including differentiated thyroid cancer; Treatment with lenvima by administering lenvima as a suspension; Treatment of patients with pmmr/not msi-h advanced endom...

Dosage: CAPSULE

How can I launch a generic of LENVIMA before it's drug patent expiration?
More Information on Dosage

LENVIMA family patents

Family Patents

11. Lytgobi patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9108973 TAIHO ONCOLOGY 3,5-disubstituted alkynylbenzene compound and salt thereof
Feb, 2033

(8 years from now)

US10434103 TAIHO ONCOLOGY Crystal of 3,5-disubstituted benzene alkynyl compound
Mar, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833151 TAIHO ONCOLOGY Pharmaceutical composition including sodium alkyl sulfate
Nov, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2027
Orphan Drug Exclusivity(ODE-410) Sep 30, 2029

Drugs and Companies using FUTIBATINIB ingredient

NCE-1 date: 30 September, 2026

Market Authorisation Date: 30 September, 2022

Treatment: Method of treating intrahepatic cholangiocarcinoma

Dosage: TABLET

More Information on Dosage

LYTGOBI family patents

Family Patents

12. Mounjaro patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION

More Information on Dosage

MOUNJARO family patents

Family Patents

13. Mounjaro (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(6 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(6 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 July, 2023

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION

More Information on Dosage

MOUNJARO (AUTOINJECTOR) family patents

Family Patents

14. Nucynta patent expiration

NUCYNTA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7994364 COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Jun, 2025

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6071970 COLLEGIUM PHARM INC Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
Jun, 2017

(7 years ago)

USRE39593 COLLEGIUM PHARM INC 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
Aug, 2022

(2 years ago)

US7994364

(Pediatric)

COLLEGIUM PHARM INC Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
Dec, 2025

(1 year, 7 days from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 20, 2013
New Patient Population(NPP) Jul 03, 2026
Pediatric Exclusivity(PED) Jan 03, 2027

Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient

NCE-1 date: 03 January, 2026

Market Authorisation Date: 15 October, 2012

Treatment: Relief of moderate to severe acute pain; Management of moderate to severe acute pain

Dosage: SOLUTION; TABLET

How can I launch a generic of NUCYNTA before it's drug patent expiration?
More Information on Dosage

NUCYNTA family patents

Family Patents

15. Ofev patent expiration

OFEV's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7119093 BOEHRINGER INGELHEIM 3-Z-[1-(4-(N-((4-Methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone-monoethanesulphonate and the use thereof as a pharmaceutical composition
Feb, 2024

(9 months ago)

US6762180 BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Oct, 2025

(9 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7989474 BOEHRINGER INGELHEIM Use of Lck inhibitors for treatment of immunologic diseases
Apr, 2024

(8 months ago)

US10154990 BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Jan, 2026

(1 year, 19 days from now)

US6762180

(Pediatric)

BOEHRINGER INGELHEIM Substituted indolines which inhibit receptor tyrosine kinases
Apr, 2026

(1 year, 3 months from now)

US10154990

(Pediatric)

BOEHRINGER INGELHEIM Medicaments for the treatment or prevention of fibrotic diseases
Jul, 2026

(1 year, 6 months from now)

US10105323 BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Jun, 2029

(4 years from now)

US9907756 BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Jun, 2029

(4 years from now)

US10105323

(Pediatric)

BOEHRINGER INGELHEIM Pharmaceutical dosage form for immediate release of an indolinone derivative
Dec, 2029

(4 years from now)

US9907756

(Pediatric)

BOEHRINGER INGELHEIM Capsule pharmaceutical dosage form comprising a suspension formulation of an indolinone derivative
Dec, 2029

(4 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 15, 2019
Orphan Drug Exclusivity(ODE) Oct 15, 2021
Orphan Drug Exclusivity(ODE-77) Oct 15, 2021
New Indication(I-805) Sep 06, 2022
New Indication(I-825) Mar 09, 2023
Orphan Drug Exclusivity(ODE-261) Sep 06, 2026
Pediatric Exclusivity(PED) Mar 06, 2027

Drugs and Companies using NINTEDANIB ESYLATE ingredient

NCE-1 date: 06 March, 2026

Market Authorisation Date: 15 October, 2014

Treatment: Treatment of idiopathic pulmonary fibrosis (ipf); Use of nintedanib for slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (ssc-...

Dosage: CAPSULE

How can I launch a generic of OFEV before it's drug patent expiration?
More Information on Dosage

OFEV family patents

Family Patents

16. Omlonti patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8648097 VISIOX PHARMA Pyridylaminoacetic acid compound
Oct, 2029

(4 years from now)

US10774072 VISIOX PHARMA Crystal of N-substituted sulfonamide compound
Jun, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8685986 VISIOX PHARMA Medical composition for treatment or prophylaxis of glaucoma
Oct, 2029

(4 years from now)

US10179127 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

USRE48183 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11793798 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10765750 VISIOX PHARMA Pharmaceutical composition containing pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11197849 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US10702511 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US9415038 VISIOX PHARMA Pharmaceutical formulations comprising a pyridylaminoacetic acid compound
Jan, 2035

(10 years from now)

US11666563 VISIOX PHARMA Pharmaceutical preparation containing pyridyl aminoacetic acid compound
Jul, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 22, 2027

Drugs and Companies using OMIDENEPAG ISOPROPYL ingredient

NCE-1 date: 22 September, 2026

Market Authorisation Date: 22 September, 2022

Treatment: Method of treating open-angle glaucoma or ocular hypertension in patients

Dosage: SOLUTION

More Information on Dosage

OMLONTI family patents

Family Patents

17. Otezla patent expiration

OTEZLA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6020358 AMGEN INC Substituted phenethylsulfones and method of reducing TNFα levels
Oct, 2018

(6 years ago)

US7893101 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Dec, 2023

(1 year, 11 days ago)

US7427638 AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Feb, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7659302 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4 methoxyphenyl)-2-methylsulfonylethyl]-4 acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 9 months ago)

US8455536 AMGEN INC Methods of using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 9 months ago)

US8802717 AMGEN INC Methods of treating arthritic conditions using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline 1,3-dione
Mar, 2023

(1 year, 9 months ago)

US7208516 AMGEN INC Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(1 year, 9 months ago)

US9018243 AMGEN INC Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
Mar, 2023

(1 year, 9 months ago)

US6962940 AMGEN INC (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
Mar, 2023

(1 year, 9 months ago)

US9724330 AMGEN INC Methods of using (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
Mar, 2023

(1 year, 9 months ago)

US7427638

(Pediatric)

AMGEN INC (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione:, and methods of synthesis and compositions thereof
Aug, 2028

(3 years from now)

US9872854 AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast
May, 2034

(9 years from now)

US10092541 AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
May, 2034

(9 years from now)

US10092541

(Pediatric)

AMGEN INC Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast
Nov, 2034

(9 years from now)

US9872854

(Pediatric)

AMGEN INC Methods for the treatment of psoriatic arthritis using apremilast
Nov, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-694) Sep 23, 2017
New Chemical Entity Exclusivity(NCE) Mar 21, 2019
New Indication(I-803) Jul 19, 2022
M(M-257) Apr 10, 2023
New Indication(I-884) Dec 20, 2024
Orphan Drug Exclusivity(ODE-248) Jul 19, 2026
M(M-299) Jul 20, 2026
Pediatric Exclusivity(PED) Jan 20, 2027
New Patient Population(NPP) Apr 25, 2027

Drugs and Companies using APREMILAST ingredient

NCE-1 date: 20 January, 2026

Market Authorisation Date: 21 March, 2014

Treatment: Use of otezla (apremilast) for the treatment of psoriatic arthritis; Treatment of patients with plaque psoriasis who are candidates for phototherapy or systemic therapy; Treatment of psoriatic arthrit...

Dosage: TABLET

How can I launch a generic of OTEZLA before it's drug patent expiration?
More Information on Dosage

OTEZLA family patents

Family Patents

18. Pluvicto patent expiration

PLUVICTO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10406240 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(3 years from now)

US11318121 NOVARTIS PSMA binding ligand-linker conjugates and methods for using
Aug, 2028

(3 years from now)

US10398791 NOVARTIS Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
Oct, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11951190 NOVARTIS Use of labeled inhibitors of prostate specific membrane antigen (PSMA), as agents for the treatment of prostate cancer
Nov, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Mar 23, 2027

Drugs and Companies using LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN ingredient

NCE-1 date: 23 March, 2026

Market Authorisation Date: 23 March, 2022

Treatment: For treatment of adult patients with prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with androgen receptor (ar) pathwa...

Dosage: SOLUTION

More Information on Dosage

PLUVICTO family patents

Family Patents

19. Pomalyst patent expiration

POMALYST's oppositions filed in EPO
POMALYST IPR and PTAB Proceedings
Can you believe POMALYST received compensation for the extended wait time during the regulatory approval process?
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8828427 BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Jun, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6476052 BRISTOL Isoindolines, method of use, and pharmaceutical compositions
Jul, 2016

(8 years ago)

US5653517 BRISTOL Process and system for determination of friction/slip characteristics of road vehicle tires
Jul, 2016

(8 years ago)

US5635517 BRISTOL Method of reducing TNFα levels with amino substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxo-and 1,3-dioxoisoindolines
Jul, 2016

(8 years ago)

US6316471 BRISTOL Isoindolines, method of use, and pharmaceutical compositions
Aug, 2016

(8 years ago)

US8158653 BRISTOL Pharmaceutical compositions of 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-amino isoindoline
Aug, 2016

(8 years ago)

US8204763 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(6 years ago)

US8589188 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(6 years ago)

US6561976 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(6 years ago)

US6908432 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(6 years ago)

US6045501 BRISTOL Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
Aug, 2018

(6 years ago)

US6561977 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(4 years ago)

US8315886 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(4 years ago)

US8626531 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(4 years ago)

US6315720 BRISTOL Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
Oct, 2020

(4 years ago)

US6755784 BRISTOL Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Oct, 2020

(4 years ago)

US8673939 BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(1 year, 7 months ago)

US8735428 BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
May, 2023

(1 year, 7 months ago)

US8735428

(Pediatric)

BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(1 year, 1 month ago)

US8673939

(Pediatric)

BRISTOL Methods for treating multiple myeloma with 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Nov, 2023

(1 year, 1 month ago)

US8198262 BRISTOL Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Jun, 2025

(5 months from now)

US8198262

(Pediatric)

BRISTOL Methods for treating multiple myeloma using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione
Dec, 2025

(11 months from now)

US9993467 BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(5 years from now)

US10555939 BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
May, 2030

(5 years from now)

US10555939

(Pediatric)

BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(5 years from now)

US9993467

(Pediatric)

BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Nov, 2030

(5 years from now)

US8828427

(Pediatric)

BRISTOL Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Dec, 2031

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 08, 2018
New Indication(I-707) Apr 23, 2018
Orphan Drug Exclusivity(ODE) Feb 08, 2020
Orphan Drug Exclusivity(ODE-43) Feb 08, 2020
M(M-14) Nov 20, 2023
Orphan Drug Exclusivity(ODE-296) May 14, 2027
Orphan Drug Exclusivity(ODE-297) May 14, 2027
Pediatric Exclusivity(PED) Nov 14, 2027

Drugs and Companies using POMALIDOMIDE ingredient

NCE-1 date: 14 November, 2026

Market Authorisation Date: 08 February, 2013

Treatment: Use of pomalidomide for the treatment of multiple myeloma; Use of pomalidomide to inhibit the secretion of pro-inflammation cytokines, including tumor necrosis factor alpha; Use of pomalidomide while ...

Dosage: CAPSULE

How can I launch a generic of POMALYST before it's drug patent expiration?
More Information on Dosage

POMALYST family patents

Family Patents

20. Pyrukynd patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8785450 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(6 years from now)

USRE49582 AGIOS PHARMS INC Therapeutic compounds and compositions
Feb, 2031

(6 years from now)

US11254652 AGIOS PHARMS INC Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
Nov, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9980961 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(7 years from now)

US10632114 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(7 years from now)

US9682080 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
May, 2032

(7 years from now)

US9193701 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Oct, 2032

(7 years from now)

US11793806 AGIOS PHARMS INC Pyruvate kinase activators for use in therapy
Apr, 2033

(8 years from now)

US11234976 AGIOS PHARMS INC Methods of using pyruvate kinase activators
Oct, 2038

(13 years from now)

US11878049 AGIOS PHARMS INC Mitapivat therapy and modulators of cytochrome P450
Jul, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 17, 2027
Orphan Drug Exclusivity(ODE-392) Feb 17, 2029

Drugs and Companies using MITAPIVAT SULFATE ingredient

NCE-1 date: 17 February, 2026

Market Authorisation Date: 17 February, 2022

Treatment: Method of using a pyruvate kinase activator for the treatment of hemolytic anemia in adults with pyruvate kinase (pk) deficiency; Method for increasing the lifetime of red blood cells (rbcs) for the t...

Dosage: TABLET

More Information on Dosage

PYRUKYND family patents

Family Patents

21. Quviviq patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9732075 IDORSIA Benzimidazole-proline derivatives
Jun, 2033

(8 years from now)

US9790208 IDORSIA Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(9 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10023560 IDORSIA Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
Dec, 2034

(9 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 07, 2027
M(M-310) Sep 30, 2027

Drugs and Companies using DARIDOREXANT HYDROCHLORIDE ingredient

NCE-1 date: 07 April, 2026

Market Authorisation Date: 07 April, 2022

Treatment: Treatment of insomnia

Dosage: TABLET

More Information on Dosage

QUVIVIQ family patents

Family Patents

22. Relyvrio patent expiration

RELYVRIO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10857162 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US11071742 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US9872865 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US10251896 AMYLYX Compositions for improving cell viability and methods of use thereof
Dec, 2033

(9 years from now)

US11583542 AMYLYX Compositions of bile acids and phenylbutyrate compounds
Jul, 2040

(15 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 29, 2027
Orphan Drug Exclusivity(ODE-411) Sep 29, 2029

Drugs and Companies using SODIUM PHENYLBUTYRATE; TAURURSODIOL ingredient

NCE-1 date: 29 September, 2026

Market Authorisation Date: 29 September, 2022

Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults

Dosage: FOR SUSPENSION

More Information on Dosage

RELYVRIO family patents

Family Patents

23. Rezlidhia patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9834539 RIGEL PHARMS Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(10 years from now)

US10532047 RIGEL PHARMS Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(14 years from now)

US12053463 RIGEL PHARMS Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(14 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10414752 RIGEL PHARMS Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(10 years from now)

US11498913 RIGEL PHARMS Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(10 years from now)

US10550098 RIGEL PHARMS Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Sep, 2035

(10 years from now)

US11013733 RIGEL PHARMS Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
May, 2039

(14 years from now)

US11497743 RIGEL PHARMS Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation
May, 2039

(14 years from now)

US11376246 RIGEL PHARMS Inhibiting mutant IDH-1
May, 2039

(14 years from now)

US10959994 RIGEL PHARMS Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
May, 2039

(14 years from now)

US11013734 RIGEL PHARMS Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
May, 2039

(14 years from now)

US11738018 RIGEL PHARMS Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
Jul, 2039

(14 years from now)

US11723905 RIGEL PHARMS Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
Nov, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 01, 2027
Orphan Drug Exclusivity(ODE-413) Dec 01, 2029

Drugs and Companies using OLUTASIDENIB ingredient

NCE-1 date: 01 December, 2026

Market Authorisation Date: 01 December, 2022

Treatment: A method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml); A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehyd...

Dosage: CAPSULE

More Information on Dosage

REZLIDHIA family patents

Family Patents

24. Solosec patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11000507 EVOFEM INC Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(10 years from now)

US11324721 EVOFEM INC Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(10 years from now)

US10335390 EVOFEM INC Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(10 years from now)

US10849884 EVOFEM INC Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(10 years from now)

US10857133 EVOFEM INC Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(10 years from now)

US10682338 EVOFEM INC Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(10 years from now)

US11602522 EVOFEM INC Secnidazole for use in the treatment of sexually transmitted infection
Sep, 2035

(10 years from now)

US11020377 EVOFEM INC Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(10 years from now)

US11000508 EVOFEM INC Secnidazole for use in the treatment of trichomoniasis
Sep, 2035

(10 years from now)

US11684607 EVOFEM INC Secnidazole for use in the treatment of bacterial vaginosis
Sep, 2035

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 15, 2022
New Indication(I-866) Jun 30, 2024
New Patient Population(NPP) Jan 26, 2025
Generating Antibiotic Incentives Now(GAIN) Sep 15, 2027

Drugs and Companies using SECNIDAZOLE ingredient

NCE-1 date: 15 September, 2026

Market Authorisation Date: 15 September, 2017

Treatment: Treatment of bacterial vaginosis in adult women; Treatment of trichomoniasis in patients 12 years of age and older; Treatment of bacterial vaginosis in female patients 12 years of age and older

Dosage: GRANULE

More Information on Dosage

SOLOSEC family patents

Family Patents

25. Sotyktu patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
USRE47929 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFNα responses
Nov, 2033

(8 years from now)

US10000480 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11021475 BRISTOL Amide-substituted heterocyclic compounds useful as modulators of IL-12, IL-23 and/or IFN alpha responses
Nov, 2033

(8 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 09, 2027

Drugs and Companies using DEUCRAVACITINIB ingredient

NCE-1 date: 09 September, 2026

Market Authorisation Date: 09 September, 2022

Treatment: Treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

Dosage: TABLET

More Information on Dosage

SOTYKTU family patents

Family Patents

26. Sunlenca patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9951043 GILEAD SCIENCES INC Therapeutic compounds
Feb, 2034

(9 years from now)

US10071985 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(12 years from now)

US11267799 GILEAD SCIENCES INC Solid forms of an HIV capsid inhibitor
Aug, 2038

(13 years from now)

US11944611 GILEAD SCIENCES INC Capsid inhibitors for the treatment of HIV
Jun, 2041

(16 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10654827 GILEAD SCIENCES INC Therapeutic compounds
Aug, 2037

(12 years from now)

US11944611 GILEAD SCIENCES INC Capsid inhibitors for the treatment of HIV
Jun, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 22, 2027

Drugs and Companies using LENACAPAVIR SODIUM ingredient

NCE-1 date: 22 December, 2026

Market Authorisation Date: 22 December, 2022

Treatment: In combination with other antiretroviral(s), for the treatment of hiv-1 infection in heavily-treatment experienced adults with multidrug resistant hiv-1 infection

Dosage: SOLUTION; TABLET

More Information on Dosage

SUNLENCA family patents

Family Patents

27. Terlivaz patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10335452 MALLINCKRODT IRELAND Method of treating patients with hepatorenal syndrome type 1
Apr, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 14, 2027
Orphan Drug Exclusivity(ODE-406) Sep 14, 2029

Drugs and Companies using TERLIPRESSIN ACETATE ingredient

NCE-1 date: 14 September, 2026

Market Authorisation Date: 14 September, 2022

Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function

Dosage: POWDER

More Information on Dosage

TERLIVAZ family patents

Family Patents

28. Trintellix patent expiration

TRINTELLIX's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7144884 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Jun, 2026

(1 year, 5 months from now)

US8722684 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8476279 TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Oct, 2022

(2 years ago)

US7144884

(Pediatric)

TAKEDA PHARMS USA Phenyl-piperazine derivatives as serotonin reuptake inhibitors
Dec, 2026

(1 year, 11 months from now)

US9227946 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US8969355 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9861630 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9125908 TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US11458134 TAKEDA PHARMS USA 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9125909 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9125910 TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Jun, 2027

(2 years from now)

US9861630

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(2 years from now)

US9125910

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(2 years from now)

US9125909

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(2 years from now)

US9125908

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(2 years from now)

US9227946

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Dec, 2027

(2 years from now)

US8969355

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1a activity for the treatment of cognitive impairment
Dec, 2027

(2 years from now)

US11458134

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimeihylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2027

(2 years from now)

US8722684

(Pediatric)

TAKEDA PHARMS USA 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
Dec, 2031

(7 years from now)

US9278096 TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Mar, 2032

(7 years from now)

US9278096

(Pediatric)

TAKEDA PHARMS USA Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
Sep, 2032

(7 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Sep 30, 2018
M(M-227) May 02, 2021
M(M-234) Oct 19, 2021
M(M-267) Nov 13, 2023
M(M-187) Jan 22, 2024
M(M-232) Aug 23, 2026
Pediatric Exclusivity(PED) Feb 23, 2027

Drugs and Companies using VORTIOXETINE HYDROBROMIDE ingredient

NCE-1 date: 23 February, 2026

Market Authorisation Date: 30 September, 2013

Treatment: Method of treating an affective disorder such as depression; Method of treating depression or major depressive disorder; Use in the treatment of major depressive disorder to improve processing speed, ...

Dosage: TABLET

How can I launch a generic of TRINTELLIX before it's drug patent expiration?
More Information on Dosage

TRINTELLIX family patents

Family Patents

29. Vabomere patent expiration

VABOMERE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8680136 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(6 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10172874 REMPEX Pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(6 years from now)

US10183034 REMPEX Therapeutic uses of pharmaceutical compositions comprising cyclic boronic acid ester derivatives
Aug, 2031

(6 years from now)

US11007206 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(6 years from now)

US9694025 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(6 years from now)

US10561675 REMPEX Cyclic boronic acid ester derivatives and therapeutic uses thereof
Aug, 2031

(6 years from now)

US11376237 REMPEX Methods of treating bacterial infections
Apr, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Aug 29, 2022
Generating Antibiotic Incentives Now(GAIN) Aug 29, 2027

Drugs and Companies using MEROPENEM; VABORBACTAM ingredient

NCE-1 date: 29 August, 2026

Market Authorisation Date: 29 August, 2017

Treatment: Treatment of complicated urinary tract infection (cuti) including pyelonephritis caused by the following susceptible microorganisms: escherichia coli, klebsiella pneumonia, and enterobacter cloacae sp...

Dosage: POWDER

More Information on Dosage

VABOMERE family patents

Family Patents

30. Veklury patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8318682 GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(4 years from now)

USRE46762 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Apr, 2029

(4 years from now)

US8008264 GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Sep, 2029

(4 years from now)

US10065958 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Sep, 2031

(6 years from now)

US11492353 GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Dec, 2031

(6 years from now)

US9724360 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(10 years from now)

US9949994 GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Oct, 2035

(10 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE46762

(Pediatric)

GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Oct, 2029

(4 years from now)

US8318682

(Pediatric)

GILEAD SCIENCES INC 1′substituted carba-nucleoside analogs for antiviral treatment
Oct, 2029

(4 years from now)

US8008264

(Pediatric)

GILEAD SCIENCES INC 1′-substituted carba-nucleoside analogs for antiviral treatment
Mar, 2030

(5 years from now)

US10065958

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Mar, 2032

(7 years from now)

US11492353

(Pediatric)

GILEAD SCIENCES INC Methods and compounds for treating Paramyxoviridae virus infections
Jun, 2032

(7 years from now)

US9724360

(Pediatric)

GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Apr, 2036

(11 years from now)

US9949994

(Pediatric)

GILEAD SCIENCES INC Methods for treating Filoviridae virus infections
Apr, 2036

(11 years from now)

US11007208 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(11 years from now)

US10695361 GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Sep, 2036

(11 years from now)

US11382926 GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Sep, 2036

(11 years from now)

US10695361

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(12 years from now)

US11382926

(Pediatric)

GILEAD SCIENCES INC Methods for treating Arenaviridae and Coronaviridae virus infections
Mar, 2037

(12 years from now)

US11007208

(Pediatric)

GILEAD SCIENCES INC Methods for treating arenaviridae and coronaviridae virus infections
Mar, 2037

(12 years from now)

US11266681 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(13 years from now)

US10675296 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(13 years from now)

US11975017 GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jul, 2038

(13 years from now)

US11266681

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US11975017

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US10675296

(Pediatric)

GILEAD SCIENCES INC Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
Jan, 2039

(14 years from now)

US11903953 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(16 years from now)

US11975012 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(16 years from now)

US11491169 GILEAD SCIENCES INC Remdesivir treatment methods
May, 2041

(16 years from now)

US11491169

(Pediatric)

GILEAD SCIENCES INC Remdesivir treatment methods
Nov, 2041

(16 years from now)

US11903953

(Pediatric)

GILEAD SCIENCES INC Remdesivir treatment methods
Nov, 2041

(16 years from now)

US11975012

(Pediatric)

GILEAD SCIENCES INC Remdesivir treatment methods
Nov, 2041

(16 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-183) Jan 21, 2025
New Patient Population(NPP) Apr 25, 2025
New Chemical Entity Exclusivity(NCE) Oct 22, 2025
M(M-301) Jul 13, 2026
Pediatric Exclusivity(PED) Jan 13, 2027

Drugs and Companies using REMDESIVIR ingredient

NCE-1 date: 13 January, 2026

Market Authorisation Date: 22 October, 2020

Treatment: Treatment of coronavirus disease 2019 (covid-19) in non-hospitalized adults and pediatric patients (birth to < 18 years of age weighing > 1.5 kg); Treatment of coronavirus disease 2019 (covid-19) in n...

Dosage: SOLUTION; POWDER

More Information on Dosage

VEKLURY family patents

Family Patents

31. Vonjo patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8153632 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
Jan, 2029

(4 years from now)

US8980873 CTI BIOPHARMA CORP 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt
Mar, 2030

(5 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9573964 CTI BIOPHARMA CORP Oxygen linked pyrimidine derivatives
May, 2028

(3 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Feb 28, 2027
Orphan Drug Exclusivity(ODE-397) Feb 28, 2029

Drugs and Companies using PACRITINIB CITRATE ingredient

NCE-1 date: 28 February, 2026

Market Authorisation Date: 28 February, 2022

Treatment: Treatment of myelofibrosis with pacritinib; Use of pacritinib for inhibiting janus associated kinase 2(jak2)

Dosage: CAPSULE

More Information on Dosage

VONJO family patents

Family Patents

32. Voquezna patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7977488 PHATHOM 1-heterocyclylsulfonyl, 2-aminomethyl, 5-(hetero-) aryl substituted 1-H-pyrrole derivatives as acid secretion inhibitors
Aug, 2028

(3 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186411 PHATHOM Pharmaceutical composition
Aug, 2030

(5 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 01, 2026
New Chemical Entity Exclusivity(NCE) May 03, 2027
New Indication(I-948) Jul 17, 2027

Drugs and Companies using VONOPRAZAN FUMARATE ingredient

NCE-1 date: 03 May, 2026

Market Authorisation Date: 01 November, 2023

Treatment: NA

Dosage: TABLET

More Information on Dosage

VOQUEZNA family patents

Family Patents

33. Vtama patent expiration

VTAMA's oppositions filed in EPO
VTAMA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11597692 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(13 years from now)

US10647649 DERMAVANT SCI Process for preparing tapinarof
Nov, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11612573 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(11 years from now)

US10426743 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(11 years from now)

US11458108 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(11 years from now)

US11622945 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(11 years from now)

US10195160 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(11 years from now)

US11617724 DERMAVANT SCI Topical pharmaceutical compositions
May, 2036

(11 years from now)

US11590088 DERMAVANT SCI Use of Tapinarof for the treatment of chronic plaque psoriasis
Nov, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 23, 2027

Drugs and Companies using TAPINAROF ingredient

NCE-1 date: 23 May, 2026

Market Authorisation Date: 23 May, 2022

Treatment: Topical treatment of plaque psoriasis in adults

Dosage: CREAM

More Information on Dosage

VTAMA family patents

Family Patents

34. Xenoview patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10583205 POLAREAN Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Feb, 2035

(10 years from now)

US11052161 POLAREAN Hyperpolarized noble gas production systems with nanocluster suppression, detection and/or filtering and related methods and devices
Dec, 2035

(11 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2027

Drugs and Companies using XENON XE-129 HYPERPOLARIZED ingredient

NCE-1 date: 23 December, 2026

Market Authorisation Date: 23 December, 2022

Treatment: NA

Dosage: GAS

More Information on Dosage

XENOVIEW family patents

Family Patents

35. Xigduo Xr patent expiration

XIGDUO XR's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6414126 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(4 years ago)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(9 months from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6936590 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2020

(4 years ago)

US9198925 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor
Oct, 2020

(4 years ago)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Apr, 2026

(1 year, 3 months from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2027

(2 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2027

(3 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
May, 2030

(5 years from now)

US7919598

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Jun, 2030

(5 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations
Nov, 2030

(5 years from now)

US8685934

(Pediatric)

ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
Nov, 2030

(5 years from now)

US9616028

(Pediatric)

ASTRAZENECA AB Bilayer tablet formulations
May, 2031

(6 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 08, 2019
M(M-238) Feb 22, 2022
New Indication(I-841) Oct 18, 2022
New Patient Population(NPP) Jun 12, 2027
Pediatric Exclusivity(PED) Dec 12, 2027

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

NCE-1 date: 12 December, 2026

Market Authorisation Date: 28 July, 2017

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazo...

Dosage: TABLET, EXTENDED RELEASE

How can I launch a generic of XIGDUO XR before it's drug patent expiration?
More Information on Dosage

XIGDUO XR family patents

Family Patents

36. Zepbound patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11918623 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 13, 2027
M(M-82) Oct 18, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...

Dosage: SOLUTION

More Information on Dosage

ZEPBOUND family patents

Family Patents

37. Zepbound (autoinjector) patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9474780 ELI LILLY AND CO GIP and GLP-1 co-agonist compounds
Jan, 2036

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Feb, 2031

(6 years from now)

US9402957 ELI LILLY AND CO Automatic injection device with delay mechanism including dual functioning biasing member
Jun, 2031

(6 years from now)

US11918623 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)

US11357820 ELI LILLY AND CO GIP/GLP1 agonist compositions
Jun, 2039

(14 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Nov 08, 2026
New Chemical Entity Exclusivity(NCE) May 13, 2027
M(M-82) Oct 18, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: 13 May, 2026

Market Authorisation Date: 28 March, 2024

Treatment: For chronic weight management in adults with an initial body mass index (bmi) of: 30 kg/m2 or greater (obesity), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related como...

Dosage: SOLUTION

More Information on Dosage

ZEPBOUND (AUTOINJECTOR) family patents

Family Patents

38. Ztalmy patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8022054 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(1 year, 11 months from now)

US8618087 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(1 year, 11 months from now)

US8318714 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(1 year, 11 months from now)

US7858609 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(1 year, 11 months from now)

US9029355 MARINUS Solid ganaxolone compositions and methods for the making and use thereof
Nov, 2026

(1 year, 11 months from now)

US9056116 MARINUS Liquid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(1 year, 11 months from now)

US8367651 MARINUS Solid ganaxolone formulations and methods for the making and use thereof
Nov, 2026

(1 year, 11 months from now)

US10603308 MARINUS Methods and compositions for treatment of epileptic disorders
Aug, 2037

(12 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jun 01, 2027
Orphan Drug Exclusivity(ODE-395) Jun 01, 2029

Drugs and Companies using GANAXOLONE ingredient

NCE-1 date: 01 June, 2026

Market Authorisation Date: 01 June, 2022

Treatment: Treatment of seizures associated with cyclin-dependent kinase-like 5 (cdkl5) deficiency disorder (cdd) in patients 2 years of age and older

Dosage: SUSPENSION

More Information on Dosage

ZTALMY family patents

Family Patents